You are here
BMS Halts Study of Hepatitis C Drug
In a brief statement, BMS said that "the cause of the safety issue and any potential relationship to study drug are unknown at this time."
The suspension is considered a major setback for the company.
The Journal noted that BMS, Gilead Sciences Inc., Abbott Laboratories, and other companies are racing to bring an oral hepatitis C drug regimen to market to replace the current standard treatment, injectable interferon, which can be difficult for patients to tolerate.